Studies in animals have shown that C60 hydrated fullerene
may have anti-amyloidogenic capacity resulting from inhibition
of the fibrillation of amyloid-beta 25–35 peptide43. A single
intracerebroventricular injection of a C60 hydrated fullerene at a
dose of 7.2 nmol/ventricle significantly improves the performance
of a cognitive task in control rats. TEM studies have confirmed
that C60 hydrated fullerene inhibits the fibrillation of amyloid-beta 25–35 peptide. This suggests a potential role for nanoparticles in the
development of therapies against amyloidogenic diseases. There is
currently no cure or reliable diagnosis until postmortem in many cases
(e.g. Alzheimer’s disease), so advances such as these are very exciting